These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 34111408)

  • 1. Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies.
    Cerutti G; Rapp M; Guo Y; Bahna F; Bimela J; Reddem ER; Yu J; Wang P; Liu L; Huang Y; Ho DD; Kwong PD; Sheng Z; Shapiro L
    Structure; 2021 Jul; 29(7):655-663.e4. PubMed ID: 34111408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A non-ACE2-blocking neutralizing antibody against Omicron-included SARS-CoV-2 variants.
    Duan X; Shi R; Liu P; Huang Q; Wang F; Chen X; Feng H; Huang W; Xiao J; Yan J
    Signal Transduct Target Ther; 2022 Jan; 7(1):23. PubMed ID: 35078968
    [No Abstract]   [Full Text] [Related]  

  • 3. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.
    Graham C; Seow J; Huettner I; Khan H; Kouphou N; Acors S; Winstone H; Pickering S; Galao RP; Dupont L; Lista MJ; Jimenez-Guardeño JM; Laing AG; Wu Y; Joseph M; Muir L; van Gils MJ; Ng WM; Duyvesteyn HME; Zhao Y; Bowden TA; Shankar-Hari M; Rosa A; Cherepanov P; McCoy LE; Hayday AC; Neil SJD; Malim MH; Doores KJ
    Immunity; 2021 Jun; 54(6):1276-1289.e6. PubMed ID: 33836142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2.
    Bracken CJ; Lim SA; Solomon P; Rettko NJ; Nguyen DP; Zha BS; Schaefer K; Byrnes JR; Zhou J; Lui I; Liu J; Pance K; ; Zhou XX; Leung KK; Wells JA
    Nat Chem Biol; 2021 Jan; 17(1):113-121. PubMed ID: 33082574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.
    Andreano E; Piccini G; Licastro D; Casalino L; Johnson NV; Paciello I; Dal Monego S; Pantano E; Manganaro N; Manenti A; Manna R; Casa E; Hyseni I; Benincasa L; Montomoli E; Amaro RE; McLellan JS; Rappuoli R
    Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34417349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody.
    Yin W; Xu Y; Xu P; Cao X; Wu C; Gu C; He X; Wang X; Huang S; Yuan Q; Wu K; Hu W; Huang Z; Liu J; Wang Z; Jia F; Xia K; Liu P; Wang X; Song B; Zheng J; Jiang H; Cheng X; Jiang Y; Deng SJ; Xu HE
    Science; 2022 Mar; 375(6584):1048-1053. PubMed ID: 35133176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2.
    Huang KA; Zhou D; Tan TK; Chen C; Duyvesteyn HME; Zhao Y; Ginn HM; Qin L; Rijal P; Schimanski L; Donat R; Harding A; Gilbert-Jaramillo J; James W; Tree JA; Buttigieg K; Carroll M; Charlton S; Lien CE; Lin MY; Chen CP; Cheng SH; Chen X; Lin TY; Fry EE; Ren J; Ma C; Townsend AR; Stuart DI
    Theranostics; 2022; 12(1):1-17. PubMed ID: 34987630
    [No Abstract]   [Full Text] [Related]  

  • 8. Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies.
    Zhu X; Mannar D; Srivastava SS; Berezuk AM; Demers JP; Saville JW; Leopold K; Li W; Dimitrov DS; Tuttle KS; Zhou S; Chittori S; Subramaniam S
    PLoS Biol; 2021 Apr; 19(4):e3001237. PubMed ID: 33914735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
    Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
    Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition.
    Kramer KJ; Johnson NV; Shiakolas AR; Suryadevara N; Periasamy S; Raju N; Williams JK; Wrapp D; Zost SJ; Walker LM; Wall SC; Holt CM; Hsieh CL; Sutton RE; Paulo A; Nargi RS; Davidson E; Doranz BJ; Crowe JE; Bukreyev A; Carnahan RH; McLellan JS; Georgiev IS
    Cell Rep; 2021 Oct; 37(1):109784. PubMed ID: 34592170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment.
    Malladi SK; Singh R; Pandey S; Gayathri S; Kanjo K; Ahmed S; Khan MS; Kalita P; Girish N; Upadhyaya A; Reddy P; Pramanick I; Bhasin M; Mani S; Bhattacharyya S; Joseph J; Thankamani K; Raj VS; Dutta S; Singh R; Nadig G; Varadarajan R
    J Biol Chem; 2021; 296():100025. PubMed ID: 33154165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
    Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
    MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization of interactions between the D614G variant of SARS-CoV-2 S-protein and neutralizing antibodies: A computational approach.
    Kwarteng A; Asiedu E; Sylverken AA; Larbi A; Sakyi SA; Asiedu SO
    Infect Genet Evol; 2021 Jul; 91():104815. PubMed ID: 33774178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD.
    Errico JM; Zhao H; Chen RE; Liu Z; Case JB; Ma M; Schmitz AJ; Rau MJ; Fitzpatrick JAJ; Shi PY; Diamond MS; Whelan SPJ; Ellebedy AH; Fremont DH
    Cell Rep; 2021 Oct; 37(4):109881. PubMed ID: 34655519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural Basis for Accommodation of Emerging B.1.351 and B.1.1.7 Variants by Two Potent SARS-CoV-2 Neutralizing Antibodies.
    Cerutti G; Rapp M; Guo Y; Bahna F; Bimela J; Reddem ER; Yu J; Wang P; Liu L; Huang Y; Ho DD; Kwong PD; Sheng Z; Shapiro L
    bioRxiv; 2021 Feb; ():. PubMed ID: 33655245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses.
    Banach BB; Cerutti G; Fahad AS; Shen CH; Oliveira De Souza M; Katsamba PS; Tsybovsky Y; Wang P; Nair MS; Huang Y; Francino-Urdániz IM; Steiner PJ; Gutiérrez-González M; Liu L; López Acevedo SN; Nazzari AF; Wolfe JR; Luo Y; Olia AS; Teng IT; Yu J; Zhou T; Reddem ER; Bimela J; Pan X; Madan B; Laflin AD; Nimrania R; Yuen KY; Whitehead TA; Ho DD; Kwong PD; Shapiro L; DeKosky BJ
    Cell Rep; 2021 Oct; 37(1):109771. PubMed ID: 34587480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antigenicity of SARS-CoV-2 Delta variants aggregated 10 high-frequency mutations in RBD has not changed sufficiently to replace the current vaccine strain.
    Wu J; Nie J; Zhang L; Song H; An Y; Liang Z; Yang J; Ding R; Liu S; Li Q; Li T; Cui Z; Zhang M; He P; Wang Y; Qu X; Hu Z; Wang Q; Huang W
    Signal Transduct Target Ther; 2022 Jan; 7(1):18. PubMed ID: 35046385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.